Metallo-␤-lactamases (MBLs) are enzymes belonging to Ambler's class B that can hydrolyze a wide variety of ␤-lactams, including penicillins, cephems, and carbapenems (14, 30, 42) . The acquisition by gram-negative rods of MBLs, which are often encoded by mobile genetic elements such as cassettes inserted into integrons, confers a multidrug resistance profile against many clinically important ␤-lactams as well as other antimicrobial agents (1) . This fact raises a significant problem with respect to antimicrobial chemotherapy (38) . Plasmid-mediated MBLs are categorized into three major molecular types: they are IMP-type, VIM-type, and SPM-type enzymes (14, 21, 30, 32, 39, 42) . Among them, IMP-1-type MBLs have been identified in various gram-negative bacilli belonging to the family Enterobacteriaceae and in several non-glucose-fermenters, such as Pseudomonas aeruginosa and Acinetobacter spp. (13, 18, 19, 20, (36) (37) (38) 43) . Furthermore, in Japan, several variants of the IMP-1 type, including IMP-3 from Shigella flexneri (15) , IMP-6 from Serratia marcescens (47) , IMP-10 from P. aeruginosa and Alcaligenes xylosoxidans (16) , and IMP-11 (EMBL/GenBank accession no. AB074437) from P. aeruginosa and Acinetobacter baumannii, have been characterized recently. VIM-type MBLs, including VIM-1 and VIM-2 from P. aeruginosa isolates in Italy and France, respectively (21, 32) , were first described in 1999. Outbreaks of VIM-type MBL-positive strains have also been reported in Italy and Greece (8, 40) . SPM-1, a member of the third group of plasmid-mediated MBLs, was recently detected in P. aeruginosa isolates in Brazil, and SPM-1 producers appear to be widely disseminated in Brazil (11) .
Previously reported survey data from the Kinki region of Japan revealed that 0.7% of isolates produced IMP-1-group MBLs (44) . The prevalence of IMP-1-group MBLs among gram-negative rods has also been investigated (19, 36) ; however, the prevalence of the new plasmid-mediated MBLs, such as the IMP-2 group (33) and the VIM-2 type (32), in Japan remains unclear.
For the present study, to assess the prevalence and types of MBL-positive bacteria in the Kinki region of Japan, we investigated almost 20,000 isolates collected from 12 general hospitals and one commercial laboratory.
MATERIALS AND METHODS
Bacterial isolates. This laboratory-based surveillance study was conducted with the cooperation of 13 institutions (12 hospital clinical laboratories and one commercial laboratory) in the Kinki region, which is located in western Japan (Fig. 1 (34) , and the amplicons were sequenced. The sequence data were submitted to the DNA Data Bank of Japan (DDBJ) database to check the identity or similarity of each sequence against the database by use of the FASTA program (http://www.ddbj.nig.ac.jp/search /Welcome-e.html).
First screening for MBL production. MIC criteria for the first screening of MBL producers were Ͼ16 g of ceftazidime/ml for Acinetobacter spp. and Ͼ16 g of both ceftazidime and cefoperazone-sulbactam/ml for gram-negative organisms other than Acinetobacter spp. The production of MBLs was assessed with a 2-mercaptopropionic acid inhibition (2-MPA) test as described previously (2, 37) . Test strains were cultured, adjusted to a 0.5 McFarland standard, diluted with 0.85% saline, and inoculated onto Mueller-Hinton agar plates according to the protocol recommended by the NCCLS (27) . Two Senci-Disks (Becton Dickinson Co., Ltd., Tokyo, Japan) containing 30 g of ceftazidime, 10 g of imipenem, and 30 g of cefepime were placed at a distance of 50 mm from each other on the plate, and one blank disk was placed near one of the Senci-Disks at a distance of 20 mm. Two to 3 l of 2-MPA was added to the blank disk. After an overnight incubation at 35°C, if an expansion of the growth inhibition zone around either the ceftazidime, imipenem, or cefepime disk was observed, the strain was interpreted as being positive for MBL.
Susceptibility testing for antimicrobial agents. The MICs of antimicrobial agents for isolates that tested positive in the 2-MPA test were subjected to antimicrobial susceptibility testing by the broth microdilution method with dry plates (Eiken Chemical Co., Ltd., Tokyo, Japan), which conformed to NCCLS guidelines (26, 28) . The following antimicrobial agents and concentrations were used: piperacillin (2 to 128 g/ml), piperacillin-tazobactam (1-4 to 128-4 g/ml), ceftazidime (1 to 128 g/ml), cefepime (1 to 128 g/ml), cefoperazone-sulbactam (1-0.5 to 128-64 g/ml), aztreonam (1 to 128 g/ml), cefmetazole (1 to 128 g/ml), moxalactam (1 to 128 g/ml), meropenem (0.25 to 32 g/ml), imipenem (0.25 to 32 g/ml), gentamicin (1 to 8 g/ml), amikacin (4 to 32 g/ml), minocycline (4 to 8 g/ml), levofloxacin (2 to 4 g/ml), trimethoprim-sulfamethoxazole (9.5-0.5 to 38-2 g/ml), and chloramphenicol (8 to 16 g/ml). E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as reference strains for quality control of the tests (26) .
PCR amplification and DNA sequencing. Isolates that tested positive in the 2-MPA test were then assessed for their MBL type by PCR and DNA sequencing. PCRs were performed as described previously (35) . PCR primers for the amplification of each MBL gene were constructed as described in previous reports for bla (35) , bla IMP-2 (33) , and bla VIM-2 (32) . Primers for the amplification of integrase genes (intI1, intI2, and intI3) (31, 37) and the aminogly- (35) were described previously. The PCR and DNA sequencing primers used are listed in Table 1 . PCR products were sequenced by the dideoxynucleotide chain termination method (45) in an automated DNA sequencer (ABI 3100; Perkin-Elmer Applied Biosystems, Foster City, Calif.). Similarity searches against sequence databases were performed with an updated version of the FASTA program available from the Center for Information Biology and DNA Data of Japan for Biotechnology Information server of the National Institute of Genetics of Japan (http://www .ddbj.nig.ac.jp/).
RAPD pattern analysis. The isolates that were confirmed to be positive for the MBL gene by PCR and chromosomal DNA typing were analyzed by random amplified polymorphic DNA (RAPD) analysis to generate a DNA fingerprint (29) . The RAPD primers were ERIC2 (5Ј-AAGTAAGTGACTGGGGTGAGC G-3Ј) for Enterobacteriaceae other than S. marcescens (41), HLWL-74 (5Ј-CGT CTATGCA-3Ј) and 1254 (5Ј-AACCCACGCC-3Ј) for S. marcescens (12) , 272 (5Ј-AGCGGGCCAA-3Ј) for P. aeruginosa (6) , and A5 (5Ј-GCCGGGGCCT-3Ј) for Acinetobacter spp. (31) .
RESULTS

Prevalence of MBL-positive isolates.
The prevalence of isolates that produced MBLs is shown in Table 2 The results of the MBL assessments in each laboratory are shown in Table 3 . These 13 laboratories included 5 laboratories in university hospitals, 7 laboratories in general hospitals, and 1 commercial laboratory. MBL-positive isolates were detected in 9 of 13 laboratories; the overall rate of detection was 0.5% and ranged from 0 to 2.6% in each laboratory.
Genetic characterization of MBL-producing isolates. Some characteristics and selected clinical associations of MBL-producing isolates are shown in Table 4 . All MBL-producing iso- ), 7 (7.3%), 4 (4.1%), 3 (3.1%), 2 (2.1%), 2 (2.1%), and 2 (2.1%) were recovered from urine, sputum, throats, pus, drains, blood, tracheal tubes, and other samples, respectively. The majority of A. baumannii isolates were recovered from respiratory tract specimens, and bacterial species belonging to the family Enterobacteriaceae and P. aeruginosa were recovered from urine.
RAPD typing with the 272 primer of 22 P. aeruginosa isolates from four hospitals identified 11 distinct types. Two or more isolates with the same banding patterns were observed for two of the four hospitals. Of 21 A. baumannii isolates from six hospitals, 8 isolates (same ward) from hospital A were found to belong to the same clonal lineage, and 5 isolates (two wards) from hospital J belonged to another clonal lineage. Of 44 S. marcescens isolates from hospitals A and C, 2 isolates from hospital A had the same pattern, and two distinct patterns were observed for 42 isolates recovered from hospital C. Forty-one of the isolates from hospital C shared the same pattern, and they had been isolated from eight different wards. At hospital C, the two isolates of Providencia rettgeri had the same pattern, and four isolates of C. freundii also shared the same pattern. Genetically related isolates, such as those of P. aeruginosa in hospital B, A. baumannii in hospitals A and J, and S. marcescens, Providencia rettgeri, and C. freundii in hospital C, were isolated from the same ward, suggesting a nosocomial spread of these organisms.
Susceptibility of MBL-producing isolates. The results of susceptibility tests are shown in Table 5 . The susceptibilities of the 96 MBL-positive isolates to several antimicrobial agents varied. For the MBL-producing bacterial species belonging to the family Enterobacteriaceae, P. aeruginosa, and Acinetobacter spp., the MICs at which 50% of the isolates were inhibited (MIC 50 s) of imipenem were 32, 16, and 16, respectively, and the MIC 90 s of the same agent were Ͼ32, 32, and 32 g/ml, respectively. For species belonging to the family Enterobacteriaceae, piperacillin-tazobactam, aztreonam, gentamicin, amikacin, and levofloxacin had relatively high activities. P. aeruginosa isolates had similar or lower susceptibilities to non-␤-lactam agents than bacterial species belonging to the family Enterobacteriaceae or Acinetobacter spp. Piperacillin-tazobactam and cefoperazone-sulbactam appeared to have the most potent activities against MBL-producing Acinetobacter spp. The MICs for E. coli ATCC 25922 and P. aeruginosa ATCC 27853 were within the NCCLS control ranges.
DISCUSSION
We investigated the distribution and prevalence of MBLproducing gram-negative rods with the cooperation of 12 clinical laboratories at large-scale general hospitals and one commercial clinical laboratory in the Kinki region of Japan. Such isolates were identified at a rate of 0.5%. In a previous laboratory-based surveillance conducted in 1998 and 2000, MBLproducing isolates were found only in specimens collected by a commercial laboratory (44) . However, MBL producers were isolated from 9 of 13 laboratories in the present multi-institutional surveillance study, and the prevalence of MBL-positive isolates ranged from 0 to 2.6%, suggesting that there is a continuous proliferation of MBL producers in Japan. The ma- jority of MBL producers detected in the present study were S. marcescens, P. aeruginosa, or Acinetobacter spp., which was similar to the results of previous studies (33, 37) . Moreover, in the present study, several strains of Providencia rettgeri and M. morganii that produce MBLs were found, suggesting that plasmid-mediated horizontal transfer of the MBL genes is so far likely to occur continuously among gram-negative bacilli, as reported previously (14, 35) . This finding gives us an alert on the further dissemination of MBL genes among various gramnegative bacilli. In the present study, the predominant type of MBL in Japan was found to be the IMP-1 group, but MBLs belonging to the IMP-2 group and the VIM-2 group were also detected. MBL genes encoding bla IMP-2 and bla VIM-2 have been reported in Italy (21, 33) , France (32), Korea (22), Taiwan (45, 46) , Portugal (7), and Greece (25) . Recently, a genetic classification of the MBLs detected in Japan was reported (37) , but the frequency of isolation of MBL producers from clinical specimens was not described. The present study provides the 
ST ( b ICU, intensive care unit; NICU, neonatal intensive care unit; MICU, medical intensive care unit; SCU, surgical care unit; CCU, coronary care unit. c Antibiogram: AMK, amikacin (64 g/ml); GM, gentamicin (16 g/ml); MINO, minocycline (16 g/ml); LVFX, levofloxacin (8 g/ml); ST, sulfamethoxazoletrimethoprim (4 g/ml); CP, chloramphenicol (32 g/ml).
first reported data on the prevalence of bacteria carrying the genes for MBLs, including IMP-1, IMP-2, and VIM-2 MBLs, in the western portion of Japan.
A total of 96 MBL-positive isolates were typed by RAPD analysis to determine the stabilities of the strain genotypes. The RAPD typing results are summarized in Table 4 . The 16 isolates of P. aeruginosa from hospital B yielded seven different RAPD patterns and originated from six different wards. Eight A. baumannii isolates from hospital A had the same RAPD pattern and were from the same ward. The five A. baumannii isolates carrying the genes for IMP-2-group MBLs, isolated from two wards of hospital J, appeared to be of the same clonal lineage. This is the first report of nosocomial spread of A. baumannii isolates carrying genes for IMP-2-group MBLs in Japan. Of the 41 S. marcescens isolates from hospital C, 13 isolates from the internal medicine coronary care unit had the same RAPD pattern and were isolated within a 5-month period, suggesting that there was probable nosocomial spread within the same ward. Thus, the same or closely related isolates were identified repeatedly by PCR fingerprinting by RAPD analysis from five hospitals, suggesting the nosocomial spread of these organisms in each hospital. Furthermore, long-term cross-transmission of plasmids that carry MBL genes among different bacterial strains and species could result in the current complicated features of MBL producers, especially in hospital B.
The 2-MPA test, which is a simple test that was first described by Arakawa et al. (2) , is a useful method for the routine laboratory detection of MBLs (45) . Moreover, in the present study, all isolates that tested positive in the 2-MPA test were subsequently confirmed to be positive for the MBL gene by PCR. However, the growth inhibition zones of bla VIM-2 -positive E. cloacae isolates were weak and ambiguous, possibly due to the excessive production of AmpC and/or a change in membrane permeability. The production of some extended-spectrum ␤-lactamases as well as the excessive production of the chromosomal AmpC cephalosporinase could be responsible for the characteristics of these strains that were previously reported for E. cloacae (2, 7) . In such cases, imipenem and meropenem disks would be better than ceftazidime disks for the detection of MBL production because imipenem and meropenem are essentially not hydrolyzed by extended-spectrum ␤-lactamases and class C cephalosporinases.
With respect to antimicrobial susceptibilities, various ␤-lactam antimicrobial agents such as ureidopenicillin, cephalosporins, cephamycins, and carbapenems had high MICs for most MBL-positive isolates, whereas monobactam and piperacillin typically had low MICs for MBL producers. Low MICs of cefepime, meropenem, and imipenem were observed for several isolates, even though MBLs can hydrolyze these agents. The production of MBLs in these isolates could be cryptic or suppressed in strains showing low-level carbapenem resistance (14) . It is also possible that IMP-3 and IMP-6 MBLs, which have low-level hydrolytic activities against these agents (15, 47) , are produced in such isolates. The increased ability of active efflux systems and decreased outer membrane permeabilities have been reported to contribute to ␤-lactam resistance in P. aeruginosa (23, 24) . Therefore, the low-level MICs of piperacillin, cefepime, and carbapenems for some isolates may be due to higher permeability coefficients or less efficient efflux pumps in the bacterial membranes in addition to the molecular mechanisms described above.
The MICs of monobactam and piperacillin for MBL producers were relatively low compared to those of oximinocephalosporins, cephamycins, and carbapenems (35, 36) ; however, this finding does not necessarily reflect their clinical efficacy against MBL producers because most gram-negative rods have the intrinsic ability to produce chromosomal AmpC cephalosporinases, which can hydrolyze monobactam and piperacillin (17) . Although the administration of high doses of aztreonam or tazobactam-piperacillin was reported to be useful for the reduction of MBL-producing strains in rats suffering from experimental pneumonia (3), it is possible that the induction of intrinsic chromosomal AmpC production in MBL producers may promote the emergence of multiple-␤-lactam-resistant gram-negative rods in clinical settings. In the present study, MICs of tazobactam-piperacillin and cefoperazone-sulbactam were generally low for MBL-positive Acinetobacter isolates. Strains producing IMP-1 or VIM-2 usually show high-level resistance to oximinocephalosporins and cephamycins, but the MIC of piperacillin for these strains is usually lower than those of oximinocephalosporins and cephamycins (9, 30, 32) . Because the activities of MBLs are not reduced significantly by ␤-lactamase inhibitors, such as sulbactam and tazobactam (5), the observations for Acinetobacter isolates suggested that the phenotypes related to these combination drugs may depend mainly on the intrinsic production of AmpC cephalosporinase (4, 10) as well as the low-level production of MBLs and alterations in membrane permeability. Thus, the low MIC levels of tazobactam-piperacillin and cefoperazone-sulbactam for MBL-producing Acinetobacter isolates could be an intrinsic feature of this bacterial genus.
In conclusion, plasmid-mediated MBL-producing gram-negative rods were first described approximately 13 years ago in Japan, and in the present study, such isolates were found to have disseminated to many hospitals in the Kinki region of Japan. It is conceivable that several isolates have spread nosocomially among a number of hospitals. The results of the present study should be considered when health care facilities develop policies and strategic practices to prevent and address the emergence and spread of MBL-producing gram-negative microorganisms in clinical environments.
